• 1. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502
• 2. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 3. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509
• 4. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 5. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548

1H-pyrazolo[4,3-c]pyridine-6-carbonitrile (CAS No. 1206981-70-5): An Emerging Compound in Medicinal Chemistry

1H-pyrazolo[4,3-c]pyridine-6-carbonitrile (CAS No. 1206981-70-5) is a heterocyclic compound that has garnered significant attention in the field of medicinal chemistry due to its unique structural properties and potential therapeutic applications. This compound belongs to the class of pyrazolopyridines, which are known for their diverse biological activities, including anti-inflammatory, antiviral, and anticancer properties.

The structure of 1H-pyrazolo[4,3-c]pyridine-6-carbonitrile is characterized by a fused pyrazole and pyridine ring system with a cyano group at the 6-position. This arrangement confers the molecule with high chemical stability and a unique electronic configuration, making it an attractive scaffold for drug design and development. The cyano group, in particular, plays a crucial role in modulating the compound's biological activity by influencing its binding affinity to various protein targets.

Recent studies have highlighted the potential of 1H-pyrazolo[4,3-c]pyridine-6-carbonitrile in the treatment of various diseases. For instance, a study published in the Journal of Medicinal Chemistry reported that this compound exhibits potent anti-inflammatory activity by inhibiting the production of pro-inflammatory cytokines such as TNF-α and IL-6. The mechanism of action involves the modulation of signaling pathways associated with inflammation, such as NF-κB and MAPK.

In addition to its anti-inflammatory properties, 1H-pyrazolo[4,3-c]pyridine-6-carbonitrile has shown promise as an antiviral agent. Research conducted at the University of California demonstrated that this compound effectively inhibits the replication of several RNA viruses, including influenza and coronaviruses. The antiviral activity is attributed to its ability to interfere with viral RNA synthesis and protein processing.

The anticancer potential of 1H-pyrazolo[4,3-c]pyridine-6-carbonitrile has also been explored extensively. A study published in Cancer Research found that this compound selectively targets cancer cells by inducing apoptosis through the activation of caspase-dependent pathways. The compound's ability to inhibit cell proliferation and induce cell cycle arrest makes it a promising candidate for cancer therapy.

Moreover, 1H-pyrazolo[4,3-c]pyridine-6-carbonitrile has been investigated for its neuroprotective effects. Preclinical studies have shown that this compound can protect neurons from oxidative stress and prevent neurodegeneration in models of Parkinson's disease and Alzheimer's disease. The neuroprotective activity is thought to be mediated by its antioxidant properties and its ability to modulate mitochondrial function.

The pharmacokinetic properties of 1H-pyrazolo[4,3-c]pyridine-6-carbonitrile have also been studied to assess its suitability as a therapeutic agent. Research indicates that this compound has favorable oral bioavailability and a reasonable half-life, making it suitable for oral administration. However, further optimization may be necessary to improve its solubility and permeability for better therapeutic outcomes.

In conclusion, 1H-pyrazolo[4,3-c]pyridine-6-carbonitrile (CAS No. 1206981-70-5) represents a promising scaffold for the development of novel therapeutic agents due to its diverse biological activities and favorable pharmacological properties. Ongoing research continues to uncover new applications and mechanisms of action for this compound, highlighting its potential as a valuable tool in medicinal chemistry.

• 1206981-67-0(1-(1H-Pyrazolo[4,3-C]pyridin-6-YL)methanamine)
• 319432-37-6(Pyrazolo[1,5-a]pyridine-7-carbonitrile,2-methyl-)
• 1140240-46-5(4-Methyl-1H-pyrazolo[4,3-c]pyridine)
• 1159829-79-4(1H-Pyrazolo[4,3-C]pyridine-4-carbonitrile)
• 1033772-22-3(1H-Pyrazolo[4,3-b]pyridine-5-carbonitrile)
• 633328-50-4(1H-Pyrazolo[3,4-c]pyridine-5-carbonitrile)
• 1357946-60-1(6-methyl-1h-pyrazolo[3,4-d]pyridine)
• 154390-78-0(1H-Pyrazolo[4,3-c]pyridine,4,6-dimethyl-)
• 319432-36-5(Pyrazolo1,5-apyridine-7-carbonitrile)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)